Onsolis available soon for breakthrough cancer pain

BioDelivery Sciences announced that Onsolis (fentanyl buccal soluble film) will be made available by Meda next week for the management of breakthrough pain in patients ≥18 years of age with cancer who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Onsolis is a C-II controlled substance and will be available in 200mcg, 400mcg, 600mcg, 800mcg, and 1600mcg dosage strengths.

For more information call (877) 466-7654 or visit www.onsolisfocus.com.